Buy Or Sell Opportunity • Jun 04
Now 232% overvalued after recent price rise Over the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%. Announcement • May 26
Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million. Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments.
The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days. Reported Earnings • May 13
First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025) First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. 
